Targeted Therapies in Breast Cancer

 
 
Oxford University Press Inc
  • erschienen am 6. November 2011
 
  • Buch
  • |
  • Spiralbindung
  • |
  • 54 Seiten
978-0-19-973567-9 (ISBN)
 
This book provides clinicians with ultra-concise, evidence-based current information and insight on implementing the latest treatment strategies, for treating breast cancer, including targeted agents, into clinical practice.
New
  • Englisch
  • New York
  • |
  • USA
  • Für Beruf und Forschung
  • |
  • General oncologists, oncology care staff, GP's and other healthcare professionals.
  • Höhe: 165 mm
  • |
  • Breite: 94 mm
  • |
  • Dicke: 8 mm
  • 68 gr
978-0-19-973567-9 (9780199735679)
weitere Ausgaben werden ermittelt
Harold J. Burstein, MD, PhD Associate Professor of Medicine Dana Farber Cancer Institute Breast Oncology Center Harvard Medical School Boston, MA
1. Introduction (epidemiology, molecular pathways)
2. Diagnosis and classification (pathological status, biomarkers (HER-2, EGFR, etc.), ER - includes discussion on triple negative status)
3. Key clinical studies
4. Approaches to treatment - mechanisms of action of available inhibitors angiogenesis agents, patient selection (tools and algorithms), sequencing of agents, adverse effects, follow-up and management
5. Triple negative disease and other challenges
6. Emerging therapeutic targets in breast cancer (i.e. Src, cell cycle, mTOR, TNF, etc.)
7. Dosing and administration guidelines for currently approved agents
8. Provider and patient resources
9. References
'Hal [Harold Burstein] is a friend and I am confident he would do a great job.'
-- William J. Gradishar, MD, Professor of Medicine, Northwestern University, Chicago, Illinois; Director, Breast Medical Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
'Dr. Burstein is certainly a knowledgeable breast cancer expert and is involved in the clinical development of many novel anti cancer drugs, including several molecularly targeted agents. The stated focus of the book appears to b e HER2, EGFR and VEGF, and these targets were selected because each has one or more commercially available 'targeted therapeutic.'
-- GN Hortobagyi, MD, FACP, Chairman and Professor in the Department of Breast Medical Oncology, Departments of Breast Medical Oncology and Molecular & Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Versand in 15-20 Tagen

20,10 €
inkl. 7% MwSt.
in den Warenkorb